Genprex (GNPX)
Market Price (3/30/2026): $1.84 | Market Cap: $27,986Sector: Health Care | Industry: Biotechnology
Genprex (GNPX)
Market Price (3/30/2026): $1.84Market Cap: $27,986Sector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -3986% | Weak multi-year price returns2Y Excs Rtn is -120%, 3Y Excs Rtn is -162% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Aging Population & Chronic Disease, and Precision Medicine. Themes include Gene Editing & Therapy, Show more. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -16 Mil | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -60582% | ||
| High stock price volatilityVol 12M is 4018% | ||
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 3156% | ||
| Key risksGNPX key risks include [1] substantial doubt about its ability to continue as a going concern due to severe cash constraints, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -3986% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Aging Population & Chronic Disease, and Precision Medicine. Themes include Gene Editing & Therapy, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -120%, 3Y Excs Rtn is -162% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -16 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -60582% |
| High stock price volatilityVol 12M is 4018% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 3156% |
| Key risksGNPX key risks include [1] substantial doubt about its ability to continue as a going concern due to severe cash constraints, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Genprex (GNPX) stock has lost about 40% since 11/30/2025 because of the following key factors:
1. Persistent Operating Losses and Financial Instability.
Genprex, a clinical-stage biotechnology company, continued to report significant operating losses, contributing to investor apprehension. The company recorded annual earnings of -$21.4 million for the fiscal year 2024. While Genprex exceeded analyst estimates for its Q3 2025 earnings, reporting an EPS of -$5.00 against an estimated -$12.50 on November 14, 2025, it remained unprofitable. This consistent cash burn inherent in clinical development cycles likely raised concerns about long-term financial viability and potential future dilution.
2. Early-Stage Pipeline and Absence of Near-Term Major Catalysts.
Despite several positive company-specific announcements during the period, these were primarily related to early-stage development or intellectual property, which were insufficient to offset investor risk perception for a deeply discounted stock. Genprex announced the addition of new clinical trial sites for its Acclaim-1 and Acclaim-3 lung cancer studies in November 2025 and reported positive preliminary preclinical data for its GPX-002 diabetes gene therapy program in January 2026. Additionally, the company received multiple patent grants in various regions between November 2025 and February 2026. However, these are early-to-mid-stage milestones, and the absence of imminent late-stage clinical trial readouts or regulatory approvals likely failed to provide the strong catalysts required to reverse the stock's significant decline.
Show more
1. Persistent Operating Losses and Financial Instability.
Genprex, a clinical-stage biotechnology company, continued to report significant operating losses, contributing to investor apprehension. The company recorded annual earnings of -$21.4 million for the fiscal year 2024. While Genprex exceeded analyst estimates for its Q3 2025 earnings, reporting an EPS of -$5.00 against an estimated -$12.50 on November 14, 2025, it remained unprofitable. This consistent cash burn inherent in clinical development cycles likely raised concerns about long-term financial viability and potential future dilution.
2. Early-Stage Pipeline and Absence of Near-Term Major Catalysts.
Despite several positive company-specific announcements during the period, these were primarily related to early-stage development or intellectual property, which were insufficient to offset investor risk perception for a deeply discounted stock. Genprex announced the addition of new clinical trial sites for its Acclaim-1 and Acclaim-3 lung cancer studies in November 2025 and reported positive preliminary preclinical data for its GPX-002 diabetes gene therapy program in January 2026. Additionally, the company received multiple patent grants in various regions between November 2025 and February 2026. However, these are early-to-mid-stage milestones, and the absence of imminent late-stage clinical trial readouts or regulatory approvals likely failed to provide the strong catalysts required to reverse the stock's significant decline.
Show more
Stock Movement Drivers
Fundamental Drivers
The -38.5% change in GNPX stock from 11/30/2025 to 3/29/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.96 | 1.82 | -38.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 0 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| GNPX | -38.5% | |
| Market (SPY) | -5.3% | 14.1% |
| Sector (XLV) | -8.7% | 15.9% |
Fundamental Drivers
The -77.8% change in GNPX stock from 8/31/2025 to 3/29/2026 was primarily driven by a 3528.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.20 | 1.82 | -77.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 0 | 3528.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| GNPX | -77.8% | |
| Market (SPY) | 0.6% | 0.5% |
| Sector (XLV) | 5.2% | 2.1% |
Fundamental Drivers
The -90.3% change in GNPX stock from 2/28/2025 to 3/29/2026 was primarily driven by a -90.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 18.85 | 1.82 | -90.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 0 | -90.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| GNPX | -90.3% | |
| Market (SPY) | 9.8% | 0.5% |
| Sector (XLV) | -2.1% | 2.1% |
Fundamental Drivers
The -99.9% change in GNPX stock from 2/28/2023 to 3/29/2026 was primarily driven by a 57.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282023 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 2560.00 | 1.82 | -99.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 0 | 57.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| GNPX | -99.9% | |
| Market (SPY) | 69.4% | 0.6% |
| Sector (XLV) | 18.4% | 1.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GNPX Return | -68% | 11% | -84% | -91% | -96% | 7% | -100% |
| Peers Return | -5% | -23% | -17% | 16% | -5% | -2% | -35% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| GNPX Win Rate | 25% | 33% | 33% | 17% | 33% | 33% | |
| Peers Win Rate | 40% | 45% | 40% | 45% | 45% | 33% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| GNPX Max Drawdown | -71% | -24% | -87% | -96% | -99% | 0% | |
| Peers Max Drawdown | -39% | -50% | -43% | -34% | -50% | -24% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: SRPT, CRSP, NTLA, BEAM, QURE.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | GNPX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -97.5% | -25.4% |
| % Gain to Breakeven | 3867.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -74.6% | -33.9% |
| % Gain to Breakeven | 294.3% | 51.3% |
| Time to Breakeven | 326 days | 148 days |
| 2018 Correction | ||
| % Loss | -98.5% | -19.8% |
| % Gain to Breakeven | 6511.2% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to SRPT, CRSP, NTLA, BEAM, QURE
In The Past
Genprex's stock fell -97.5% during the 2022 Inflation Shock from a high on 2/8/2021. A -97.5% loss requires a 3867.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Genprex (GNPX)
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
AI Analysis | Feedback
1. An early-stage Amgen, specializing in gene therapies for cancer and diabetes.
2. Like a clinical-stage Vertex Pharmaceuticals, developing gene therapies for lung cancer and diabetes.
AI Analysis | Feedback
- REQORSA (GPX-001): A lead product candidate, this gene therapy is in development for the treatment of non-small cell lung cancer and small cell lung cancer.
- GPX-002: A preclinical stage gene therapy being developed for diabetes.
AI Analysis | Feedback
Genprex, Inc. (GNPX) is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes. As a clinical-stage company, its products (REQORSA and GPX-002) are currently in various stages of clinical trials and preclinical development, respectively. They have not yet received regulatory approval for commercial sale.
Therefore, Genprex does not currently have major customers that purchase its therapeutic products. The company's primary activities involve research and development, conducting clinical trials, and pursuing regulatory approvals rather than commercial sales.
AI Analysis | Feedback
null
AI Analysis | Feedback
Ryan M. Confer, MS President, Chief Executive Officer, and Chief Financial Officer
Ryan M. Confer was appointed President and Chief Executive Officer of Genprex in May 2024, and has served as the company's Chief Financial Officer since September 2016. He joined Genprex in 2011, serving in various capacities including business manager, and Chief Operating and Financial Officer. Mr. Confer has over ten years of entrepreneurial experience in planning, launching, developing, and growing emerging technology companies, and has held C-level and Vice President roles in several early-stage technology companies since 2008. Notably, he was the VP of Customer Experience and then VP of Strategy for KaiNexus, Inc., a software company focused on continuous improvement. Prior to his entrepreneurial endeavors, Mr. Confer was a business development consultant for the University of Texas at Austin's IC2 Institute, where he assessed the commercialization potential of nascent technologies. From 2006 to 2009, he also managed a $500 million early-stage technology investment fund. Mr. Confer has consulted for Genprex since its inception in 2009 through his own firm, Confer Capital, Inc.
Mark Berger, M.D. Chief Medical Officer
Dr. Mark Berger was appointed Chief Medical Officer of Genprex in September 2021. Before joining Genprex, he served as Senior Vice President-Clinical Research at Kadmon Corporation from 2013 to 2017, where he was responsible for all aspects of new drug development, including oncology programs in non-small cell lung cancer and breast cancer. Prior to Kadmon, Dr. Berger was Chief Medical Officer of Deciphera Pharmaceuticals from June 2011 to September 2013, and before that, Vice President for Clinical Development at Gemin X Pharmaceuticals, where he led clinical strategy and trial management for two oncology agents.
Thomas Gallagher, Esq. Senior Vice President of Intellectual Property & Licensing
Thomas Gallagher serves as the Senior Vice President of Intellectual Property & Licensing at Genprex.
Suzanne Thornton-Jones, Ph.D. Senior Vice President, Regulatory Affairs and Quality
Suzanne Thornton-Jones is the Senior Vice President, Regulatory Affairs and Quality at Genprex.
David M. Schloss Senior Vice President of Human Resources
David M. Schloss holds the position of Senior Vice President of Human Resources at Genprex.
AI Analysis | Feedback
Here are the key risks to Genprex's business:
- Clinical Trial Failure and Regulatory Approval: As a clinical-stage gene therapy company, Genprex's success hinges on its ability to successfully complete clinical trials for its lead product candidates, REQORSA (GPX-001) for lung cancer and GPX-002 for diabetes, and subsequently obtain regulatory approvals. The development of novel gene therapies is subject to extensive and evolving regulatory requirements, and changes in these policies or increased scrutiny could delay or prevent product approval. Failures in clinical trials, delays in enrollment, or inability to meet primary or secondary endpoints would severely impact the company's valuation and future prospects.
- Financing and Liquidity: Genprex faces significant operational risks due to its need for substantial additional funding to continue the development and potential commercialization of its product candidates. The company has a history of recurring losses and an accumulated deficit, and it does not expect to be profitable in the foreseeable future. This raises substantial doubt about its ability to continue as a going concern, indicating a reliance on future equity offerings, collaborations, or other financing arrangements, which could lead to significant shareholder dilution or even cessation of operations if not secured.
- Competition and Market Acceptance: Genprex operates in highly competitive markets for gene therapy, oncology, and diabetes treatments. It faces competition from various biotechnology and pharmaceutical companies, many of which possess greater financial resources and more extensive research and development capabilities. These competitors may develop more effective or widely accepted products, potentially diminishing the market opportunity for Genprex's drug candidates.
AI Analysis | Feedback
nullAI Analysis | Feedback
Genprex, Inc. (NASDAQ: GNPX) operates in the addressable markets of non-small cell lung cancer, small cell lung cancer, and diabetes.
REQORSA (GPX-001) for Lung Cancer
- Non-Small Cell Lung Cancer (NSCLC): The global non-small cell lung cancer therapeutics market was valued at approximately USD 38.49 billion in 2025 and is projected to grow to approximately USD 74.99 billion by the end of 2034. In North America, the market was valued at USD 17.15 billion in 2025 and is anticipated to maintain a dominant share.
- Small Cell Lung Cancer (SCLC): The global small cell lung cancer therapeutics market size is projected to be approximately USD 6.52 billion in 2025, with an expected increase to USD 17.59 billion by 2033. North America accounted for over 40% of the global revenue in 2025, with a market size of approximately USD 2.61 billion.
GPX-002 for Diabetes
- Diabetes Gene Therapy / Next-Generation Diabetes Therapy: The global Next Generation Diabetes Therapy and Drug Delivery market size was approximately USD 10.22 billion in 2024 and is expected to grow to approximately USD 27.51 billion by 2031. North America held a major market share of over 40% of the global revenue in 2024, with a market size of approximately USD 4.09 billion.
- Overall Diabetes Treatment Market: More broadly, the global diabetes drugs market was valued at approximately USD 99.88 billion in 2024 and is projected to reach approximately USD 218.8 billion by 2032. North America accounted for 21% of the market share in 2023.
AI Analysis | Feedback
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, is currently a pre-revenue company, meaning its future revenue growth is entirely dependent on the successful clinical development and eventual commercialization of its lead product candidates. Over the next 2-3 years, the primary drivers of future revenue growth will stem from critical advancements in its oncology and diabetes gene therapy programs.
Here are 3-5 expected drivers of future revenue growth for Genprex:
- Advancement of REQORSA (GPX-001) in Non-Small Cell Lung Cancer (NSCLC) through Clinical Trials: The progression of the Acclaim-1 clinical trial for REQORSA in combination with Tagrisso to treat NSCLC is a key driver. The successful completion of the Phase 1 portion and the ongoing Phase 2a expansion, with an interim analysis expected by the end of 2026 and the potential start of Phase 2b in 2027, will be crucial milestones toward regulatory submission and potential market entry. Positive outcomes from these trials could demonstrate efficacy and safety, paving the way for future regulatory approvals and commercialization in a significant market.
- Advancement of REQORSA (GPX-001) in Small Cell Lung Cancer (SCLC) through Clinical Trials: The continued progress of the Acclaim-3 Phase 1/2 clinical trial, evaluating REQORSA in combination with Tecentriq for SCLC, is another vital driver. REQORSA has already received Fast Track Designation and Orphan Drug Designation from the U.S. FDA for SCLC, which could expedite its development and review process. Successful trial results would move the company closer to regulatory approval and market access for this difficult-to-treat cancer.
- Initiation and Progression of Human Clinical Trials for GPX-002 in Diabetes: Genprex's diabetes gene therapy candidate, GPX-002, which targets both Type 1 and Type 2 diabetes, has shown positive preclinical data. A significant driver will be the successful engagement with the FDA for Investigational New Drug (IND)-enabling studies, with a meeting scheduled for the first quarter of 2026. The subsequent initiation and progression of human clinical trials for GPX-002 would be a critical de-risking event and a substantial step towards realizing future revenue potential, even if commercialization is beyond the immediate 2-3 year horizon.
- Strategic Partnerships and Collaborations: While not a direct product, the company's ability to establish and leverage strategic partnerships for the development, manufacturing, and potential commercialization of its therapies is a significant driver. Genprex has already undertaken manufacturing scale-up for REQORSA and engaged Contract Development and Manufacturing Organizations (CDMOs) for GPX-002. Such collaborations can provide necessary resources, expertise, and market access, thereby accelerating the path to market for its innovative gene therapies.
AI Analysis | Feedback
Share Issuance
- Genprex had 2.32 million shares outstanding (as of March 2026).
- The number of shares outstanding increased by 922.94% in one year.
- The company executed a 1-for-50 reverse stock split on October 21, 2025.
Capital Expenditures
- Genprex's capital expenditures were listed as "n/a" in one financial overview.
- The company's free cash flow of -$15.08 million provided weak coverage of capital expenditures, which were indicated as "1" (likely a negligible amount).
- Genprex generated -$1.7 million in free cash flow in Q3 2024, representing cash available after capital expenditures.
Trade Ideas
Select ideas related to GNPX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 17.37 |
| Mkt Cap | 1.8 |
| Rev LTM | 42 |
| Op Inc LTM | -412 |
| FCF LTM | -338 |
| FCF 3Y Avg | -281 |
| CFO LTM | -275 |
| CFO 3Y Avg | -265 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 15.6% |
| Rev Chg 3Y Avg | 33.9% |
| Rev Chg Q | 6.6% |
| QoQ Delta Rev Chg LTM | 2.2% |
| Op Mgn LTM | -463.1% |
| Op Mgn 3Y Avg | -661.8% |
| QoQ Delta Op Mgn LTM | 78.4% |
| CFO/Rev LTM | -415.1% |
| CFO/Rev 3Y Avg | -517.6% |
| FCF/Rev LTM | -421.3% |
| FCF/Rev 3Y Avg | -531.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.8 |
| P/S | 18.8 |
| P/EBIT | -4.6 |
| P/E | -4.1 |
| P/CFO | -5.9 |
| Total Yield | -25.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -20.0% |
| D/E | 0.1 |
| Net D/E | -0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -9.6% |
| 3M Rtn | -13.3% |
| 6M Rtn | -25.0% |
| 12M Rtn | 9.2% |
| 3Y Rtn | -46.0% |
| 1M Excs Rtn | -6.3% |
| 3M Excs Rtn | -6.8% |
| 6M Excs Rtn | -21.3% |
| 12M Excs Rtn | -6.8% |
| 3Y Excs Rtn | -108.9% |
Price Behavior
Price Behavior
| Market Price | $1.82 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/29/2018 | |
| Distance from 52W High | -91.6% | |
| 50 Days | 200 Days | |
| DMA Price | $2.18 | $6.68 |
| DMA Trend | down | down |
| Distance from DMA | -16.5% | -72.7% |
| 3M | 1YR | |
| Volatility | 119.0% | 4,042.4% |
| Downside Capture | 0.48 | 2.66 |
| Upside Capture | 118.40 | 104.23 |
| Correlation (SPY) | 14.4% | 0.4% |
GNPX Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.54 | 1.10 | 1.40 | 0.11 | 0.58 | 0.79 |
| Up Beta | 8.57 | 2.79 | 0.58 | -5.48 | 0.30 | 0.80 |
| Down Beta | 3.94 | 1.98 | 1.73 | 134.72 | 30.03 | 18.49 |
| Up Capture | -310% | 83% | 22% | 101% | 127% | -6% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 7 | 17 | 22 | 43 | 101 | 297 |
| Down Capture | -157% | -34% | 248% | 313% | 171% | 113% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 12 | 20 | 35 | 77 | 143 | 437 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GNPX | |
|---|---|---|---|---|
| GNPX | -90.5% | 4,018.5% | 0.97 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 2.1% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 0.3% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | -23.4% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | -6.2% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | -0.8% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | -3.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GNPX | |
|---|---|---|---|---|
| GNPX | -82.2% | 1,805.7% | 0.41 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 1.2% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 1.0% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | -15.9% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | -2.1% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 0.0% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | -1.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GNPX | |
|---|---|---|---|---|
| GNPX | -57.5% | 1,435.4% | 0.36 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 1.8% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 1.7% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | -13.0% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | -1.3% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 1.2% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | -0.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 04/01/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/21/2023 | 10-Q |
| 03/31/2023 | 05/22/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/13/2022 | 10-Q |
| 12/31/2021 | 03/30/2022 | 10-K |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.